SEP 05 2008
PATENT & TRADEMARK OFFICE

PTO/SB/08A (07-05)
Approved for use through 09/30/2008. OMB 0651-0031

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1 of 1

Complete if Known	
Application Number	10/681,753
Filing Date	October 9, 2003
First Named Inventor	Christopher G. WILLIAMS
Group Art Unit	1657
Examiner Name	Laura J. SCHUBERG
Attorney Docket Number	CART-001/01US (305165-2019)

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-5,700,848	12-23-1997	Soon-Shiong, P., *et al.*	
	2	US-5,837,747	11-17-1998	Soon-Shiong, P., *et al.*	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	3	WO 94/25080	11-10-1994	GRIFFITH-CIMA, L., *et al.*		
	4	WO 93/17669	09-16-1993	HUBBELL, J. *et al.*		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Unique citation designation number (optional). [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

SEP 05 2008
PATENT & TRADEMARK OFFICE

PTO/SB/08B (07-05)
Approved for use through 09/30/2008. OMB 0651-0031

Substitute for form 1449A/PTO		*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/681,753
		Filing Date	October 9, 2003
		First Named Inventor	Christopher G. WILLIAMS
(use as many sheets as necessary)		Group Art Unit	1657
		Examiner Name	Laura J. SCHUBERG
Sheet	1 of 2	Attorney Docket Number	CART-001/01US (305165-2019)

OTHER – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	1	BENSON, Roberto, Nuclear Instruments and Methods in Physics Research B 191, 2002, pgs. 752-757	
	2	AYDELOTTE, M. *et al.*, "Differences between sub-populations of cultured bovine articular chondrocytes. I: Morphology and cartilage matrix production" Connective Tissue Res., Vol. 18, pgs, 205-221 (1998)	
	3	AYDELOTTE, M. *et al.*, "Differences between sub-populations of cultured bovine articular chondrocytes. II: Proteoglycan metabolism" Connective Tissue Res., Vol. 18, pgs 223-234 (1998)	
	4.	BUCKWALTER, J. *et al.*, "Articular Cartilage Part I: Tissue Design and chondrocytes-matrix interactions" The Journal of Bone and Joint Surgery, Vol. 79-A, pgs. 600-611 (1997)	
	5	BUCKWALTER, J. *et al.*, "Articular Cartilage Part II: Degeneration and osteoarthritis, repair, regeneration, and transplantation" The Journal of Bone and Joint Surgery , Vol. 79-A, pgs. 612-632 (1997)	
	6	ELISSEEFF, J. *et al.*, "Biological Response of chondrocytes to hydrogels" Ann. N.Y. Acad. Sci. Vol. 961, pgs. 118-122 (2002)	
	7	ELISSEEFF, J. *et al.*, "Photoencapsulation of chondryocytes in poly(ethylene oxide)-based semi-interpenetrating networks" J. Biomed. Master. res., Vol. 51, pgs. 164-171 (2000)	
	8	ELISSEEFF, J. *et al.*, "Transdermal photopolymerization for minimally invasive implantation" Proc. Nat'l. Acad. Sci. USA, Vol. 96, pgs. 3104-3107 (1999)	
	9	HEALY, K. *et al.*, "Designing Biomaterials to Direct Biological Responses" Ann. NY Acad. Sci., Vol. 875, pgs. 24-24 (1999)	
	10	HUBBELL, Jeffrey A. "Bioactive Biomaterials" Curr. Opin. Biotechnol. , Vol. 10, pgs. 123-129	
	11	KIM, T.K. *et al.*, "Experimental Model for Cartilage Tissue Engineering to Regenerate the Zonal Organization of Articular of Cartilage" Osteoarthritis and Cartilage, Vol. 11, pgs 653-664 (2003)	
	12	KIM, T.K. *et al.*, Tissue engineering of stratified articular cartilage from chondrocyte subpopulations" Osteoarthritis and Cartilage, Vol. 11, pgs 595-602 (2003)	
	13	KORVER, G. *et al.*, "Composition of Proteoglycans Synthesized in Different Layers of Cultured Anatomically Intact Articular Cartilage" Matrix, Vol. 10, pgs. 394-401 (1990)	
	14	QUINN, T. *et al.*, "Controlled Enzymatic Matrix Degradation for Integrative Cartilage Repair: Effects on Viable Cell Density and Proteoglycan Deposition" Tissue Engineering, Vol. 8, pgs. 799-806	
	15	SAWHNEWY, A. *et al.*, "Bioerodible Hydrogels Based on Photopolymerized Poly(ethyleneglycol)-co-poly(α-hydroxy acid) Diacrylate Macromers" Macromolecules, Vol. 26, pgs 581-587 (1993)	
	16	SICZKOWSKI, M. *et al.*, "Subpopulations of chondrocytes from different zones of pig articular cartilage: Journal of Cell Science, Vol. 97, pgs 349-360 (1990)	
	17	SOLCHAGA, L. *et al.*, "Experimental Models of Cartilage Repair: Cartilage Regeneration Using Principles of Tissue Engineering" Clinical Orthopaedics and Related Research, Vol. 391S, pgs S161-S170 (2001)	

Please type a plus sign (+) inside this box → [+]

SEP 05 2008
PATENT & TRADEMARK OFFICE

PTO/SB/08B (07-05)
Approved for use through 09/30/2008. OMB 0651-0031

Substitute for form 1449A/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(use as many sheets as necessary)*		***Complete if Known***	
		Application Number	10/681,753
		Filing Date	October 9, 2003
		First Named Inventor	Christopher G. WILLLIAMS
		Group Art Unit	1657
		Examiner Name	Laura J. SCHUBERG
Sheet	2 of 2	Attorney Docket Number	CART-001/01US (305165-2019)

	18	TEMENOFF, J. *et al.*, "Review: tissue engineering for regeneration of articular cartilage" Biomaterials, Vol. 21, pgs 431-440 (2000)	
	19	WALDMAN, S. *et al.*, "The use of specific chondrocyte populations to modulate the properties of tissue-engineered cartilage" Journal of Orthopaedic Research, Vol. 21, pgs 132-138 (2003)	
	20	WONG, M. *et al.*, "Zone-Specific Cell Biosynthetic Activity in Mature Bovine Articular Cartilage: A New Method Using Confocal Microscopic Stereology and Quantitative Autoradiography" Journal of Orthopaedic Research, Vol. 14, pgs 424-432 (1996)	
	21	ASSAM, T. *et al.*, "Cationic Polysaccharides for Gene Delivery" Macromolecules, Vol. 35, pgs 9947-9953 (2002)	
	22	CHEN, Y-R. *et al.*, "An Electron Spin Resonance Spin-trapping Investigation of the Free Radicals Formed by the Reaction of Mitochondrial Cytochrome c Oxidase with H_2O_2" The Journal of Biological Chemistry, Vol. 274, pgs. 3308-3314 (1999)	
	23	LI, Q. *et al.*, "Heterogeneous-Phase Reaction of Glycidyl Methacrylate and Chondroitin Sulfate: Mechanism of Ring-Opening-Transesterification Competition" Macromolecules, Vol. 36, pgs. 2556-2562 (2003)	
	24	HAI, T. *et al.*, "Surface Modification of Diaspirin Cross-linked Hemoglobin (DCLHb) with Chondroitin-4 sulfate Derivatives. Part 1" Bioconjugate Chem., Vol. 11, pgs. 705-713 (2000)	
	25	BENSON, R. *et al.*, "Use of radiation in biomaterials science" Nucl. Instr. and Meth. in Phys. Res., Vol. B191, pgs. 752-757 (2002)	
	26	QIAN, S. *et al.*, "Identification of protein-derived tyrosyl radical in the reaction of cytochrome c and hydrogen peroxide: characterization by ESR spin-trapping, HPLC and MS" Biochem. J., Vol. 363, pgs. 281-288 (2002)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Unique citation designation number (optional). [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.